Frontlight ResearchEarly access
Obesity trials in Czechia
33 of 36 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
- Where
- Brandýs nad Labem, Brno, Brno-Královo Pole, Brno-Stred, Brno-Zidenice, Broumov, Bruntal, Chlumec nad Cidlinou, Chomutov, Havířov, Holesov, Horni Brana, Horni Predmesti, Hradec Králové, Jaroměř, Liberec, Melnik, Moravska Ostrava A Privoz, Náchod, Olomouc, Ostrava, Pardubice, Pardubice I, Prague, Prague 1, Prague 2, Prerov I-Mesto, Prostějov, Slaný, Uherske Hradiste, Uherské Hradiště, Usti nad Labem, Ústí nad Labem, Valasske Mezirici
- Age
- 18 years and over
- People
- 2,787 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-516654-22-00 - Phase 3Active, not recruitingA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- České Budějovice, Náchod, Plzeň 3, Prague, Prague 4, Praha 2
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Brandýs nad Labem, Jesenice, Prague, Prague 6, Praha, Praha 6
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Not yet taking people in CzechiaA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Where
- Brno, České Budějovice, Habry, Moravska Ostrava A Privoz, Prague, Praha 9, Uherské Hradiště
- Age
- 18 years and over
- People
- 2,001 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07794579 · EU 2026-526175-35-00 - Phase 3Not yet taking people in CzechiaA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
- Where
- Brandýs nad Labem, Brno-Stred, Lazce, Náchod, Ostrava, Prague
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07843485 · EU 2026-526189-25-00 - Phase 3Taking peopleMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Where
- Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
- Age
- 18 years to 70 years
- People
- 350 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937086 · EU 2024-520209-38-00 - Phase 3Taking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
- Age
- 18 years to 70 years
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - No phaseTaking peopleNational Childhood Obesity Prevention Programme BE FIT 24
- Where
- Prague
- Age
- 6 years to 11 years
- People
- 1,000
- Run by
- Institute of Health Information and Statistics of the Czech Republic
See details and how to joinNCT07057453 - Phase 3Active, not recruitingA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
- Where
- Benešov, Brno, Karlovy Vary, Náchod, Olomouc, Ostrava, Pilsen, Prague
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07202884 · EU 2025-522514-23-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Where
- Krnov, Ostrava, Prague 1, Praha 1
- Age
- 18 years and over
- People
- 1,035 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00 - Phase 3Taking peopleEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Where
- Brno-Sever, Brno-Stred, Ostrava, Pardubice I, Uherské Hradiště
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07353931 · EU 2025-523768-19-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Where
- Holešov, Prague, Prague 8, Praha 4
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00 - Phase 3Not yet taking people in CzechiaA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Where
- Náchod, Nový Jičín, Prague, Roudnice Nad Labem, Usti Nad Labem
- Age
- 45 years to 64 years
- People
- 3,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00 - Phase 3Taking peopleMaridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy (MARITIME-OSA-2)
- Where
- Benesov, Brno, Moravska Ostrava A Privoz
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Amgen Inc.
See details and how to join2025-522699-94-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Benešov, Brno-Stred, Hodonín, Kladno, Moravska Ostrava A Privoz, Prague, Prague 10, Prague 14, Sedlcany, Steti, Votice
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - Phase 3Taking peopleEfficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
- Where
- Pardubice, Praha 2, Praha 5, Uherské Hradiště
- Age
- 18 years and over
- People
- 932 worldwide
- Run by
- Ascletis Pharma (China) Co. Ltd.
See details and how to join2026-526172-23-00 - Phase 3Taking peopleMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Where
- Brandýs nad Labem, Brno, Broumov, Bruntál, Chlumec nad Cidlinou, Chomutov, Havirov - Mesto, Holešov, Hradec Králové, Jaroměř, Liberec, Mělník, Náchod, Olomouc, Ostrava, Pardubice, Prague, Praha 5 - Smichov, Přerov, Prostějov, Slaný, Trutnov, Uherské Hradiště, Ústí nad Labem
- Age
- 18 years to 99 years
- People
- 5,056 worldwide
- Run by
- Amgen
See details and how to joinNCT07037459 - Phase 3Taking peopleEfficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
- Where
- Pardubice, Praha 2, Praha 5, Uherské Hradiště
- Age
- 18 years and over
- People
- 549 worldwide
- Run by
- Ascletis Pharma (China) Co. Ltd.
See details and how to join2026-526336-39-00 - No phaseNot yet taking people in CzechiaExercise Snacks Enabled by an mHealth Intervention Delivered in General Practice to Promote a Sustainable Active Lifestyle in Adults With Obesity
- Where
- Ostrava, Prague
- Age
- 18 years to 65 years
- People
- 306
- Run by
- Charles University, Czech Republic
See details and how to joinNCT07867665 - Phase 3Taking peopleA Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
- Where
- Brandýs nad Labem, Brno, Broumov, České Budějovice, Chlumec Nad Cidlinou Iv, Chrudim IV, Hodonín, Horni Predmesti, Humpolec, Konska, Louny, Mariánské Lázně, Olomouc, Prague, Prague 13, Prague 2, Prague 8, Praha, Přerov, Prerov I-Mesto, Prostějov, Říčany, Slaný, Smiřice, Uherské Hradiště, Zlín
- Age
- 45 years to 64 years
- People
- 8,500 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07861100 · EU 2026-525182-53-00 - Phase 3Taking peopleMaridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)
- Where
- Benesov, Brno, Moravska Ostrava A Privoz
- Age
- 18 years and over
- People
- 115 worldwide
- Run by
- Amgen Inc.
See details and how to join2025-522703-14-00 - Phase 3Active, not recruitingA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Where
- Brno-Stred, Dolní Břežany, Liberec, Náchod, Plzeň 3, Prague, Praha 22
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07564414 · EU 2025-522488-14-00 - Phase 3Not yet taking people in CzechiaA Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Where
- Pardubice, Prague, Uherské Hradiště
- Age
- 18 years and over
- People
- 1,560 worldwide
- Run by
- Ascletis Pharma (China) Co., Limited
See details and how to joinNCT07743450 - Phase 3Not yet taking people in CzechiaA Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- Where
- Pardubice, Prague, Uherské Hradiště
- Age
- 18 years and over
- People
- 3,003 worldwide
- Run by
- Ascletis Pharma (China) Co., Limited
See details and how to joinNCT07743463 - No phaseTaking peopleENDOPLY System in Humans: a Pilot Study
- Where
- Brno
- Age
- 18 years to 60 years
- People
- 10
- Run by
- ENDOPLY
See details and how to joinNCT06292728